Citations

Clear

1417 citation(s) found for "Li, Simon".

Six-Year Trends in ICU Admission, Management, and Outcomes of Chimeric Antigen Receptor T-Cell Patients in the ICU
Rajendram, Prabalini , Stephens, R. Scott , Brown, Anne Rain T., Nates, Joseph L., Dharshan, Ananda, Hensley, Matthew K., Feng, L., McEvoy, Colleen , Ibikunle, Sikemi, Beasley, Melissa, Mead, Elena, Kostelecky, Natalie, Mucha, Simon , Mian, Agrima , Ahmed, Sairah, Tharwani, Arsal, Hill, Brian T. , Lin, Yi, Gutiérrez, Cristina , Initiative, and the Chimeric Antigen Receptor for the ICU (CAR-ICU), Gutierrez, Cristina , Brown, Anne Rain , May, Heather P. , Nates, Joseph L. , Pastores, Stephen M. , Moraes, Alice Gallo de , Hensley, Matthew K. , Ibikunle, Sikemi, Westin, Jason R. , Ahmed, Sairah , Tharwani, Arsal , Herr, Megan M.

Mayo Clinic

Critical Care Medicine | December 30, 2025 | Volume: 54 | Issue: 3 | Pages: 422-434

10.1097/ccm.0000000000007000 | PMID 41467744 Get It

Objectives: To evaluate evolving management, ICU admission, and outcomes for critically ill chimeric antigen receptor (CAR) T-cell patients over a 6-year period. Design: Multicenter retrospective cohort study from January 2018 to September 2023. Setting: Eight U.S. centers. Patients: Adult CAR T-cell patients requiring ICU admission. Interventions: None. Methods: Summary statistics included mean, sd , median, and interquartile range (IQR). Fisher exact test or chi-square test were used to evaluate association between year treated and other categorical variables. Cochran-Armitage test was performed to assess significance of trends across years. Multivariable logistic regression was performed to assess covariates associated with mortality. Measurements and Main Results: Demographics, toxicity management, ICU admission, support modalities, toxicity severity, and survival (ICU, hospital, and 3-mo) were compared year-to-year. From 2018 to 2023, 2238 patients received CAR T cells, with increasing number of patients treated yearly; 398 (17.8%) required ICU care. Of those admitted to the ICU, 66.1% were male, 89.2% had lymphoma, and median age was 64 years (53–71 yr). ICU admission rates declined from 38.5% (95% CI, 31.6–45.8%) in 2018 to 16.4% in 2023 (95% CI, 13.5–19.7%; p < 0.0001). Cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome was the reason for ICU admission in 87.9%. In 2023 vs. 2018, ICU patients were older (median, 65 yr [IQR, 55–73 yr] vs. 58 yr [48–67 yr]; p = 0.003) with higher comorbidity indices (4 [4–6] vs. 3 [2–4]; p = 0.005) and more severe toxicities (≥ grade 3: 90.1% vs. 69.9%; p = 0.004). Corticosteroid use for less severe toxicities (≤ grade 2 toxicity: 73.8% vs. 40.6%; p = 0.0001) and anakinra use (56% vs. 5.5%; p < 0.0001) increased throughout the years. Mortality from cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome remained low (5.5%). Age, Sequential Organ Failure Assessment greater than or equal to 10 at ICU admission, and ICU admission for noncytokine release/neurotoxicity syndrome reasons were associated with hospital mortality (odds ratios, 1.02 [95% CI, 1–1.04; p = 0.046], 4.69 [2.44–9.01; p < 0.0001], and 3.74 [1.91–7.3; p = 0.0001], respectively). Conclusions: ICU admission rates after CAR T-cell treatment are declining. Although ICU patients are older with higher severity of illness and toxicity grades, ICU mortality after CAR T-cell therapy remains low.
The Concise Guide to PHARMACOLOGY 2025/26: Catalytic receptors
Alexander, S P H , Fabbro, Doriano , Peach, Chloe J. , Gibb, Alasdair J. , Kelly, Eamonn , Mathie, Alistair , Veale, Emma L. , Armstrong, Jane F , Faccenda, Elena , Harding, Simon D , Beuve, Annie, Brouckaert, Peter, Burnett, John C., Friebe, Andreas, Garthwaite, John, Hobbs, Adrian J., Koesling, Doris, Kuhn, Michaela, Leitinger, Birgit , Potter, Lincoln R., Russwurm, Michael, Schmidt, Harald H. H. W., Stasch, Johannes‐Peter, Waldman, Scott A., Alexander, Stephen P H , Mathie, Alistair A , Southan, Christopher , Davies, Jamie A , Bryant, Clare , Farndale, Richard W , Jarvis, Gavin E , Kilpatrick, Laura , Leitinger, Birgit , MacEwan, David , Monie, Tom P , Veale, Emma L , Armstrong, Jane F , Faccenda, Elena , Harding, Simon D , Peach, Chloe J. , Gibb, Alasdair J. , Kelly, Eamonn , Beuve, Annie , Brouckaert, Peter, Burnett, John C., Farndale, Richard, Friebe, Andreas , Garthwaite, John, Hobbs, Adrian J., Koesling, Doris , Kuhn, Michaela, Potter, Lincoln R., Russwurm, Michael, Schmidt, Harald , Stasch, Johannes‐Peter, Waldman, Scott A.

Mayo Clinic

British Journal of Pharmacology | December 30, 2025 | Volume: 182 | Issue: S1 | Pages: No page available

10.1111/bph.70233 | PMID 41461584 Get It

The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear, accessible, and well‐structured, rather than the scope of the content, which spans approximately 500 pages. The Concise Guide summarises the key pharmacological properties of around 1900 human drug targets, and nearly 7000 interactions, involving around 4400 ligands. While the content is a substantially condensed version of the more detailed information and links available at the www.guidetopharmacology.org website, the printed guide serves as a permanent, citable, point‐in‐time record, that remains stable despite ongoing updates to the online database. The full contents of this publication can be found at https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.70233 . The Concise Guides provide expert‐curated recommendations of ‘Gold Standard’ selective pharmacological tools, available either commercially or as donations, which enable the identification of individual drug targets or families of drug targets. While the Concise Guide offers a more streamlined overview, more comprehensive information, including detailed pharmacological profiles and links to multiple online databases, is available through the Guide to Pharmacology website. The 2025/26 edition of the Concise Guide is based on material current as of mid‐2025, and supersedes all previous editions, including the 2023/24 Guide, and earlier Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC‐IUPHAR), and as such provides official IUPHAR classification and nomenclature for human drug targets, where applicable. Catalytic receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein‐coupled receptors, ion channels, nuclear hormone receptors, enzymes and transporters. Each section includes nomenclature guidance, concise summaries, information of the best available pharmacological tools, key references, and suggestions for further reading.
Genetic and Pathological Characteristics of Frontotemporal Dementia with Right Anterior Temporal Predominance: A Multicenter Retrospective Cohort Study
Ulugut, Hülya , Spinelli, Edoardo G., Samancı, Bedia , Santillo, Alexander , Waldö, Maria Landqvist , Riedl, Lina , Stock, Jan Van den, Vandenbulcke, Mathieu, Vandenberghe, Rik, Laforce, Robert, Ducharme, Simon , Pressman, Peter , Tartaglia, Carmela M., Caramelli, Paulo, Souza, Leonardo Cruz de, Takada, Leonel Tadao, Morin, Alexandre , Schroeter, Matthias L, Kim, Eun‐Joo, Moon, So Young, Agosta, Federica, Filippi, Massimo, Gürvit, Hakan, Galimberti, Daniela, Miller, Bruce L., Sturm, Virginia E. , Miyagawa, Toji , Whitwell, Jennifer L., Boeve, Brad F, Rohrer, Jonathan D., Tempini, Maria Luisa Gorno , Josephs, Keith A., Warren, Jason D. , Rankin, Katherine, Group, International rtvFTD Working, Agosta, Federica , Spinelli, Edoardo Gioele , Agosta, Federica , Younes, Kyan , Bertoux, Maxime , Montembeault, Maxime , Fumagalli, Giorgio , Ghirelli, Alma , Jung, Na‐Yeon , Illán‐Gala, Ignacio , Thompson, J. C. , Kobylecki, Christopher , Englund, Elisabet , Stock, Jan Van den , Vandenbulcke, Mathieu , Vandenberghe, Rik , Laforce, Robert , Caramelli, Paulo , Souza, Leonardo Cruz de , Takada, Leonel Tadao , Schroeter, Matthias L , Kim, Eun‐Joo , Moon, So Young , Canu, Elisa , Filippi, Massimo , Gurvit, Hakan I. , Diehl‐Schmid, Janine , Galimberti, Daniela , Lebouvier, Thibaud , Miller, Bruce L. , Whitwell, Jennifer L. , Rohrer, Jonathan D. , Josephs, Keith A. , Snowden, Julie S. , Rankin, Katherine P. , Pijnenburg, Yolande A.L.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2025 | Volume: 21 | Issue: S3 | Pages: No page available

10.1002/alz70857_103987 Get It

Abstract Background Frontotemporal dementia (FTD) with right anterior temporal lobe (RATL) predominant atrophy is an emerging area of interest. Recent findings by the International Working Group (IWG) have identified this subtype as having a distinct clinical profile within the FTD spectrum (Ulugut et al., 2024, A&D). However, its genetic and pathological underpinnings remain unexplored in large, multicultural cohorts. Methods Retrospective analyses encompassing clinical, genetic, pathological, and neuroimaging data from 23 IWG sites across 13 countries in Asia, Middle East, Europe, North and South America were conducted. The study included 444 patients with FTD exhibiting predominant RATL atrophy. Results Genetic screening was performed on 51% ( n = 225) of the cohort for at least the major frontotemporal lobar degeneration (FTLD) mutations including microtubule‐associated protein tau ( MAPT ), progranulin ( GRN ), and chromosome 9 open reading frame 72 ( C9orf72 ), or dementia panels encompassing extended sets of genes. Of these, 81% were sporadic, showing negative results for the screened genes and a modified Goldman Score of ≥ 3, indicating a negative family history for dementia. The MAPT mutation was the most common genetic variant, identified in 7% of the screened cases (Figure 1). Pathological confirmation was available for 63 patients. Among the sporadic cases, transactive response DNA‐binding protein 43 type C (TDP‐C) pathology was most prevalent (60%, n = 32), while tau‐MAPT pathology was most common in the genetic cases (38%, n = 16). Fifteen cases did not fit neatly into genetic or sporadic categories, displaying heterogeneous pathologies (Figure 2). At the initial visit, compared to genetic cases, patients with TDP‐C pathology were older, and more frequently exhibited semantic deficits, with less frequent attention difficulties and executive dysfunction. No differences were observed in sex distribution, symptom duration or disease severity between genetic and sporadic TDP‐C cases. However, left handedness was more common in TDP‐C cases (14%) compared to genetic cases (5%). Conclusion While FTD with RATL atrophy primarily appears sporadic, a significant proportion of cases exhibit genetic variants. These sporadic and genetic subtypes display distinct neuropathological features and clinical manifestations. Given the implications for therapeutic strategies, precise clinical and molecular subtyping is critical for enhancing patient management and ensuring appropriate enrollment in clinical trials.
Boron‐Doped Nano‐Crystalline Coated Carbon Fibers for Phasic Dopamine Sensing
Higham, Simon , Cabrera, Juan M. Rojas , Kwak, Youngjong , Hong, Lydia, Chambers, Andre , Nadarajah, Athavan, León, Sorel E. De , Jung, Young Jun , Jalilinejad, Negin , Jang, Dong Pyo , Shin, Hojin , Tong, Wei , Higham, Simon J , Blaha, Charles , Lee, Kendall, Shin, Hojin , Tong, Wei , Rojas Cabrera, Juan M , Hong, Lydia, Blaha, Charles D. , Oh, Yoonbae , Lee, Kendall , Stacey, Alastair D. , Cloherty, Shaun Liam , Ibbotson, Michael R. , Garrett, David J. , Prawer, Steven

Mayo Clinic

Advanced Healthcare Materials | December 18, 2025 | Volume: 15 | Issue: 15 | Pages: No page available

10.1002/adhm.202503945 | PMID 41409014 Get It

ABSTRACT Real time, chronic electrochemical detection of neurotransmitters will provide a positive step in the treatment and understanding of neurological disease. However, current electrodes using carbon fibers (CF) fail to perform chronically. While diamond‐based coatings show promise in improving their longevity, achieving a uniform layer of such coatings on CFs is challenging, and the electrodes often lose sensitivity after coating. In this work, a complete and uniform boron‐doped nanocrystalline material grown in a diamond reactor (B‐NCD) was developed to coat CF microelectrodes for neurochemical sensing. The coating was characterized electrically, optically, mechanically, and chemically. The B‐NCD coated CF electrodes were able to detect phasic dopamine at a sensitivity comparable to the most widely used alternatives (uncoated and PEDOT:Nafion coated CFs). During biofouling testing, the B‐NCD coated CF electrodes demonstrated better stability than uncoated CFs and comparable performance to PEDOT:Nafion coated CFs. Moreover, B‐NCD exhibited no signs of degradation during consecutive FSCV applications, while uncoated and PEDOT:Nafion coated CF electrodes degraded significantly over time. Furthermore, the B‐NCD coating supported the survival and development of neurons and astrocytes in vitro, exhibited excellent adhesion and durability during mechanical bending testing, and enabled successful in vivo recording of phasic dopamine release in the rat brain. Overall, B‐NCD coated CFs present as an ideal candidate for chronic, flexible neural implantable electrodes for long‐term neurochemical monitoring.
NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025
Mehren, Margaret von, Kane, John M., Armstrong, Samantha A., Balach, Tessa, Bishop, Andrew J., Buehler, Darya, Carr-Ascher, Janai, Choy, Edwin, Cipriano, Cara, Connolly, Mary, Dann, Amanda, Davis, Elizabeth J., Dry, Sarah, Eulo, Vanessa, Ganjoo, Kristen N., Gonzalez, Ricardo J., Viveiros, Pedro A. Hermida De, Hitchcock, Ying J., Kim, Edward, Lefler, Daniel, Liebner, David, McCarter, Martin, McGarry, Sean V., Mesko, Nathan W., Meyer, Christian, Motamedi, Kambiz, Movva, Sujana, Pappo, Alberto S., Pollack, Seth M., Poppe, Matthew, Riedel, Richard F., Robinson, Steven, Schuetze, Scott M., Sicklick, Jason K., Tseng, William W., Weiss, Mia C., Zimel, Melissa, Hang, Lisa E., Bergman, Mary Anne, Diwan, Zeenat, Pappo, Alberto S. , Riedel, Richard F. , Riedel, Richard F , Mehren, Margaret von, Kane, John M., Armstrong, Samantha A., Balach, Tessa, Bishop, Andrew J., Buehler, Darya, Carr-Ascher, Janai, Choy, Edwin, Cipriano, Cara, Connolly, Mary, Dann, Amanda, Davis, Elizabeth J., Dry, Sarah, Eulo, Vanessa Anne , Ganjoo, Kristen N., Gonzalez, Ricardo J., Viveiros, Pedro A. Hermida De, Hitchcock, Ying J., Kim, Edward, Lefler, Daniel, Liebner, David, McCarter, Martin, McGarry, Sean V., Mesko, Nathan W., Meyer, Christian, Motamedi, Kambiz, Movva, Sujana, Pollack, Seth M., Poppe, Matthew, Robinson, Steven, Schuetze, Scott M., Sicklick, Jason K., Tseng, William W., Weiss, Mia C., Zimel, Melissa, Hang, Lisa E., Bergman, Mary Anne, Diwan, Zeenat

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 17, 2025 | Volume: 23 | Issue: 12 | Pages: 498-506

10.6004/jnccn.2025.0058 | PMID 41671462 Get It

The treatment landscape for soft tissue sarcomas (STS) is evolving constantly. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for STS specific to surgical management and systemic therapy recommendations for various subtypes.
Effect of Previous Embolization on Radiation-Induced Changes After Stereotactic Radiosurgery for Brain Arteriovenous Malformations
Mokua, Collins , Ramirez-Garcia, Kristina , Nguyen, Justin H. , Lee, Cheng‐Chia , Ding, Dale , Woo, Shiao Y. , Kondziolka, Douglas, Feliciano, Caleb , Rodriguez-Mercado, R, Cockroft, Kevin M. , Simon, Scott D. , Lee, John Y. K., Sheehan, Jason P. , Chen, Ching-Jen , Ding, Dale , Becerril‐Gaitan, Andrea , Nguyen, Justin, Cifarelli, Christopher P. , Liščák, Roman , Williams, Brian J. , Yusuf, Mehran Behruj , Warnick, Ronald E. , Trifiletti, Daniel M. , Mathieu, David , Chen, Ching‐Jen

Mayo Clinic

Neurosurgery | December 16, 2025 | Volume: 99 | Issue: 3 | Pages: 593-602

10.1227/neu.0000000000003880 | PMID 41400380 Get It

BACKGROUND AND OBJECTIVES: Stereotactic radiosurgery (SRS) for brain arteriovenous malformations (AVMs) can cause radiation-induced changes (RIC), but its interactions with AVM embolization are not well established. The aim of this study was to assess the effect of previous embolization on RIC in SRS-treated AVM patients. METHODS: Data of AVM patients treated with single-session SRS from 1987 to 2018 were retrieved from the International Radiosurgery Research Foundation. Univariable and stepwise backward logistic regression models were used to identify RIC predictors. Patients were stratified into those who received pre-SRS embolization (E + SRS) vs those who did not (SRS-only). Radiologic RIC (rRIC) was the primary end point. Secondary outcomes included symptomatic RIC (sRIC) and permanent symptomatic RIC (pRIC). RESULTS: Among 1187 AVM patients, the mean age was 36.4 years (SD 16.8), with 50.4% female patients. AVMs had a mean untreated AVM volume of 5.2 cm 3 . A total of 130 patients (11%) underwent neoadjuvant embolization (E + SRS). The overall rRIC and sRIC rates were 32.8% and 12.1%, respectively, with time to rRIC and sRIC being significantly longer in the E + SRS vs SRS-only cohorts (103.6 ± 339.4 vs 11.3 ± 12.5 and 60.4 ± 262.9 vs 9.5 ± 9.0 months, respectively). Seizures at presentation and ≥3-cm untreated AVM volume significantly correlated with a higher likelihood of rRIC (adjusted odds ratio [aOR] 2.32 [1.25-4.30] and aOR 2.77 [1.24-6.16], respectively). Age and pre-SRS embolization were associated with a significantly lower risk of rRIC (aOR 0.97 [0.96-0.99] and aOR 0.32 [0.13-0.74], respectively). The E + SRS cohort had significantly reduced odds of rRIC (aOR = 0.37 [0.15-0.89]) and pRIC (aOR = 0.04 [0.00-0.30]) after adjusting for significant covariates. CONCLUSION: Seizures at presentation and larger untreated AVM volume were independently associated with an increased risk of rRIC, whereas older age and pre-SRS embolization were protective. Notably, patients who underwent embolization before SRS had lower odds of rRIC and pRIC, with delayed onset of complications compared with SRS-only.
Mortality in immune TTP remains unpredictable: Shortcomings of prediction models despite machine learning advances
Kashinath, Sanjana Kalvehalli , Singal, Mukul , Singh, Rishabh , Bechara, Simon, Peterson, Cecilia, Lee, Ho Jun , Mitchell, Carley , Nayak, Lalitha , Investigators, USTMA, Singal, Mukul , Singh, Rishabh , Abou-Ismail, Mouhamed Yazan , Sridharan, Meera , Khouri, Ashley , Kandula, Manasa , Zhang, Chong , Kouides, Peter A. , Mazepa, Marshall , Lim, Ming

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3105-3105

10.1182/blood-2025-3105 Get It

Abstract Background Despite advances in the diagnosis and treatment of immune thrombotic thrombocytopenic purpura (iTTP), recent mortality estimates remain around 5–10%. Predicting iTTP mortality risk has been of interest, as it may help individualize treatment or potentially guide the use of more intensive or novel therapies based on disease severity. However, prior attempts at mortality prediction have yielded inconsistent results, and no individual variable has demonstrated independent or reliable predictive ability. In a previous analysis utilizing the USTMA iTTP registry, which included 419 patients from 15 TTP referral centers, we reported that mortality due to immune TTP was unpredictable (Blood. 2021;138[Suppl 1]:1047). Neither the French Thrombotic Microangiopathy (TMA) Reference Score (previously validated in the French TMA Registry), nor a previous logistic regression model attempt (developed by USTMA investigators in 2021) demonstrated sufficient accuracy in predicting iTTP mortality in the USTMA dataset (AUC = 0.63 and 0.69, respectively). We subsequently utilized gradient boosted machine, a machine learning approach capable of handling multiple continuous variables and the complex interactions between them in large datasets, and developed a novel prediction tool: the USTMA Mortality Index (Res Pract Thromb Haemost. 2024; 8(3):102388). It demonstrated good performance in predicting iTTP mortality (AUC = 0.77) in repeated 10-fold cross-validation. However, it has not yet undergone external validation. Objectives To externally validate the USTMA Mortality Index to predict mortality due to acute iTTP in a multicenter cohort. Methods We performed an external validation using an independent cohort of iTTP patients from 5 institutions: University of Utah, Case Western Reserve University, Rochester Regional Health, University of Illinois, and Mayo Clinic. Patients in the validation cohort were not part of the development cohort (the USTMA registry). We included patients with confirmed iTTP and defined acute iTTP mortality as death within 30 days of admission. USTMA Mortality Index variables were collected at initial presentation, which included (in order of highest to lowest relative influence): lactate dehydrogenase, serum creatinine, age, hemoglobin, platelet count, presence of stupor/coma, fever. The model's prediction accuracy was assessed using area under the receiver operating characteristic curve (AUC). We calculated sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) based on the previously defined cut-offs of 4.27% and 9.08% mortality risk in the original model, which categorized patients into standard risk, high risk, and very high risk of predicted mortality. Results The external validation cohort included 103 patients with confirmed iTTP and 11 deaths (10.7% mortality rate). The USTMA Mortality Index demonstrated poor performance with AUC of 0.69 (95% CI, 0.55–0.83) in the validation cohort. The wide confidence interval reflects substantial uncertainty in model performance, ranging from poor to excellent, and is likely due to the small number of deaths. At a risk threshold ≥4.27%:Sensitivity = 64%Specificity = 70%PPV = 20%NPV = 94% At a risk threshold ≥9.08%:Sensitivity = 18%Specificity = 87%PPV = 14%NPV = 90% Conclusion The USTMA Mortality Index demonstrated poor performance in the external validation cohort (AUC = 0.69, 95% CI, 0.55–0.83), contrasting with its previously favorable performance in repeated 10-fold cross-validation. This discrepancy likely reflects model overfitting, a known challenge in AI-based clinical modeling. Our study is limited by the small number of deaths, resulting in a wide confidence interval ranging from poor to excellent performance. Given that neither the French TMA Reference Score, nor our group's prior logistic regression model (2021), nor the USTMA Mortality Index (2024) could reliably predict mortality upon external validation in our cohorts, these findings collectively suggest that mortality in acute iTTP remains difficult to predict at this time, regardless of statistical methodology or current machine learning capabilities. Clinical decision-making, including the use of therapies such as caplacizumab, should not be guided solely by mortality risk predictions. Instead, efforts to reduce mortality and improve outcomes should prioritize individualized clinical assessment over model-based stratification at this time.
Immune thrombocytopenia in patients treated with immune checkpoint inhibitors
Leaf, Rebecca Karp , Mones, Jodi V. , Shenoy, Tushar , Warsame, Mohamed , Panch, Sandhya R. , Leavitt, Andrew D. , Zon, Rebecca L. , Shahamatdar, Sahar , Lim, Tristan , Cui, Can , Kaunfer, Sarah Allison , Durai, Lavanya , Sha, Carrie , Holmes, Aaron N., Easwar, Neela, Corley, Elizabeth M. , Zhao, Ethan, Li, Xingyi , Spelman, Amy, Amos, Christina, Soebbing, Doris, Shabih, Maria, Jamieson, Trevor, Hussein, Guleid , Yadav, Sumeet Kumar, Juras, Patrick K. , Heskel, Marina, Reynolds, Kerry, Kroll, Michael H. , Easton, Neil , Easton, Neela , Moreira, Marina Beltrami , Kendall, Ellen K. , Jiang, Debbie , Dias, Julie‐Alexia , Li, Xingyi, Amos, Christina, Jamieson, Trevor, Liu, Bolun , Elsaid, Mohamed I , Owen, Dwight H , Meara, Alexa Simon , Suresh, Arvind , Huang, Jennifer J , Glezerman, Ilya G , Go, Ronald S. , Al‐Samkari, Hanny , Leaf, David E.

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 841-841

10.1182/blood-2025-841 Get It

Abstract INTRODUCTION Immune checkpoint inhibitors (ICIs) have emerged as a cornerstone of cancer therapy. However, despite their efficacy, ICIs can cause a unique spectrum of autoimmune toxicities known as immune-related adverse events (irAEs). In contrast to irAEs involving other organ systems, hematologic irAEs such as ICI-associated immune thrombocytopenia (ICI-ITP) are less common. As a result, existing data on ICI-ITP are largely confined to isolated case reports, single-center case series, and pharmacovigilance databases lacking granular clinical data. To address this key knowledge gap, we sought to comprehensively characterize the incidence, risk factors, clinical features, treatments, and outcomes associated with ICI-ITP. METHODS We performed a multicenter cohort study of adult patients who initiated ICI therapy at 29 hospitals across 7 major cancer centers in 11 geographically diverse states in the US between 2016-2023. ICI-ITP was defined as a decline in platelet count to &lt;100 x109/L in the absence of an alternative more plausible etiology of thrombocytopenia. Patients with hematologic malignancies were excluded, as were those who received cytotoxic chemotherapy within 30 days prior to thrombocytopenia onset. For each patient identified as having ICI-ITP, we collected data on demographics, comorbidities, medications, laboratory values, treatments, and outcomes. All data were extracted by manual chart review. To identify risk factors for ICI-ITP and to examine its association with death, for each case of ICI-ITP we also collected data on two control patients who initiated ICI therapy at the same site and in the same year but without development of ICI-ITP. We used multivariable logistic regression to identify independent risk factors for ICI-ITP and its recovery (the latter defined according to criteria established by the ITP International Working Group). We used a multivariable Cox model to examine the association between ICI-ITP and its severity with all-cause mortality. RESULTS We identified a total of 214 patients who developed ICI-ITP among 86,648 examined (0.25%). The incidence was highly consistent across sites (range, 0.15–0.30%). Risk factors for ICI-ITP included simultaneous receipt of two different classes of ICIs, additional irAEs, and a lower baseline platelet count. ICI-ITP developed at a median of 8 weeks (IQR, 4–18) following ICI initiation. The median nadir platelet count was 41 x109/L (IQR, 17–64). Six out of 214 patients (2.8%) developed a major bleed, and 16 patients (7.5%) developed a clinically relevant non-major bleed. Cell-bound anti-platelet antibody testing was positive in 6 of 8 patients (75.0%) for whom it was assessed, and median circulating thrombopoietin levels (201 pg/mL [IQR, 178–295]) were similar to those seen in primary ITP. Treatments used included glucocorticoids (49.5%), immune globulin (18.2%), and thrombopoietin receptor agonists (13.6%). Overall, 161 patients (75.2%) recovered from ICI-ITP at a median of 2 weeks (IQR, 1–5) following ICI-ITP onset. Predictors of recovery included additional irAEs and a higher nadir platelet count. Treatment response was observed in 57.0%, 56.4%, and 58.3% of patients within 60 days following initiation of glucocorticoids, immune globulin, and thrombopoietin receptor agonists, respectively. Of 76 patients rechallenged with an ICI, 23 (30.3%) developed recurrent ICI-ITP at a median of 9 weeks (IQR, 2–15); 17 of these 23 patients (73.9%) recovered. Finally, ICI-ITP and its severity were monotonically associated with a higher risk of death (adjusted hazard ratio 2.96 [95% CI, 2.14–4.08] for those with severe ICI-ITP compared to those without ICI-ITP). CONCLUSION In this multicenter study involving patients treated with ICIs at 29 hospitals across the US, we identified 214 patients with ICI-ITP. For the first time, we characterize in detail the incidence, risk factors, clinical features, treatments, and outcomes of ICI-ITP, a relatively novel disease entity. We found that more than half of patients responded to conventional ITP-directed therapies, and that most patients rechallenged did not develop recurrent ICI-ITP. We also found that ICI-ITP was independently associated with an increased risk of death, including a nearly 3-fold increased risk in those with severe ICI-ITP. These findings highlight ICI-ITP as a rare but clinically significant complication of ICI therapy that hematologists must be equipped to recognize and manage.
Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age
Voorhees, Peter M. , Cohen, Yaël C. , Lindsay, Jindriska, Suzuki, Kenshi , Beksaç, Meral , Magen, Hila , Garate, Gonzalo, Theunissen, Koen, Mylin, Anne K., Hallam, Simon , Bringhen, Sara, Uttervall, Katarina , Ye, J Christine, Cowan, Andrew J. , Mateos, María‐Victoria , Goldschmidt, Hartmut , Vieyra, Diego, Raval, Ashta, Sha, Linlin, Rousseau, Els, Dennis, Robyn M., Carson, Robin, Dimopoulos, Meletios Α. , Schjesvold, Fredrik , Hungria, Vânia , Sandhu, Irwindeep , Baker, Ross , Kosugi, Hiroshi , Levin, Mark-David , Stockerl‐Goldstein, Keith , Oriol, Albert , Mikala, Gábor , Špıčka, Ivan , Bringhen, Sara, Puła, Bartosz , Khan, Abdullah , Medvedova, Eva , Moreau, Philippe, Raval, Ashta, Li, Liang , Carson, Robin, Rajkumar, S. Vincent

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 372-372

10.1182/blood-2025-372 Get It

Abstract Introduction : Current standard of care for smoldering multiple myeloma (SMM), an asymptomatic precursor of multiple myeloma (MM), is observation until progression to active MM. Increasing evidence suggests that patients (pts) with SMM at high risk for progression to active MM may benefit from early treatment (tx). In AQUILA, a phase 3 study in pts with high-risk SMM (NCT03301220), daratumumab (Dara) monotherapy significantly reduced risk of progression to active MM or death with a trend of extending overall survival (OS) vs active monitoring (ActMon), with no new safety concerns. Given the evolution in SMM risk stratification, a post hoc analysis was performed to assess outcomes using the IMWG 2020 and IMWG 2020 plus cytogenetic risk models to assess which AQUILA pts benefited most from Dara monotherapy. Safety and efficacy analysis by age and stem cell collection outcomes were also assessed. Methods: Eligible pts with a confirmed diagnosis (≤5 y) of high-risk SMM per IMWG 2014 criteria, defined as clonal bone marrow plasma cells (BMPC) ≥10% and ≥1 risk factor (IgA SMM, serum protein ≥30 g/dL, serum involved:uninvolved free light chain [I/U FLC] ratio ≥8 and &lt;100, immunoparesis with reduction of 2 uninvolved Ig isotypes, and/or clonal BMPC &gt;50% to &lt;60%) at study entry, were randomized 1:1 to receive subcutaneous Dara or ActMon for 39 cycles, 36 months, or until confirmed disease progression (PD), whichever came first. Primary endpoint was progression-free survival (PFS) assessed by independent review committee, defined as progression to active MM (based on IMWG SLiM-CRAB diagnostic criteria) or death. Secondary endpoints included time to first-line (1L) MM tx and OS. For this post hoc analysis, we assessed outcomes by age, IMWG 2020 high-risk SMM criteria (BMPC &gt;20%, monoclonal spike &gt;2 g/dL, serum FLC ratio &gt;20; ≥2 factors=high risk; also known as the Mayo 2018 or the 20-2-20 criteria), and the IMWG 2020 plus cytogenetic criteria (IMWG 2020 criteria + presence of ≥1 high-risk cytogenetic abnormalities [t(4;14), t(14;16), +1q and/or del13q]; ≥3 factors=high risk). Results : Dara tx showed a PFS benefit across all IMWG 2020 risk subgroups (low: hazard ratio [HR], 0.59; intermediate: HR, 0.70), with the largest benefit in the high-risk subgroup, where the PD/death rate in the ActMon arm was ~1.6-fold that in the Dara arm (62.8% vs 37.5%; HR, 0.36). This benefit of Dara vs ActMon was preserved over time, with 5-year PFS rates of 78.2% vs 71.6%, 56.2% vs 42.9%, and 60.4% vs 23.6% in IMWG 2020 low-, intermediate-, and high-risk groups, respectively. There was a positive trend favoring Dara for time to 1L MM treatment across all IMWG 2020 risk groups (low-risk HR, 0.63; 95% CI, 0.22–1.80; intermediate-risk HR, 0.57; 95% CI, 0.35–0.92; high-risk HR, 0.39; 95% CI, 0.25–0.62). IMWG 2020 plus cytogenetic risk classification results will be available at the time of presentation. When comparing the younger (&lt;65y HR, 0.51; 95% CI, 0.32–0.79) vs the older (≥65y, HR, 0.50; 95% CI, 0.32–0.77) pt population, a PFS benefit was observed regardless of age. Similarity was also observed in TEAE incidence rate when looking into &lt;65, 65 to &lt;75, and ≥75 y subgroups (82.7%, 81.1%, and 87.5% with ActMon; 96.2%, 98.5%, and 95.2% with Dara); however, serious TEAEs were more frequently observed in older ActMon pts (12.2%, 18.9%, and 50.0% with ActMon; 24.8%, 35.8%, and 28.6% with Dara). Across all pts treated/monitored in AQUILA, 23 (11.9%) and 41 (20.9%) pts in the Dara and ActMon arms, respectively, received autologous stem cell transplant as part of their first tx after progressing to active MM, with very limited plerixafor use (Dara, 3 [1.6%] vs ActMon, 9 [4.6%]). Median (range) CD34+ cell yield was 5.0 (2–20)×106 cells/kg body weight among 22 pts in the Dara arm and 5.1 (2–21)×106 cells/kg body weight among 39 pts in the ActMon arm. Conclusions : In this analysis, pts with high-risk SMM from the phase 3 AQUILA study treated with Dara monotherapy experienced long-term PFS benefit across IMWG 2020 subgroups, with the most pronounced benefit in the high-risk subgroup. No notable differences in PFS or safety were observed across age subgroups. Early Dara tx for high-risk SMM did not have a detrimental impact on stem cell yield. Although mature OS analyses are forthcoming, overall, these results further support early intervention with Dara monotherapy vs ActMon among pts with high-risk SMM, regardless of risk stratification criteria used.